Lyell Immunopharma Announces Strategic Board And Executive Hires To Advance Clinical Pipeline And Commercial Growth

Lyell Immunopharma, Inc., a clinical-stage biotechnology company focused on developing next-generation CAR T-cell therapies for cancer patients, has announced several key leadership appointments. Mark J. Bachleda, PharmD, MBA, has joined the company’s Board of Directors as an independent member. David Shook, MD, has been appointed as Chief Medical Officer, bringing with him extensive experience in oncology and clinical development. In addition, Mark Meltz, JD, has taken on the role of General Counsel and Corporate Secretary, adding legal and corporate governance expertise to the leadership team.

Lynn Seely, MD, Lyell’s President and Chief Executive Officer, said in a statement, “As Lyell prepares to move forward with two pivotal programs designed to advance LYL314 towards approval for patients with aggressive large B-cell lymphoma, we are delighted to welcome leaders who further strengthen and bring new expertise to our Board of Directors and our Executive Committee. Collectively, these new leaders have deep cell therapy expertise and highly relevant experience launching new medicines for patients. We look forward to their contributions as we continue to make progress on achieving our mission of bringing next-generation cell therapies to patients with cancer.”

Rick Klausner, MD, Chairman of the Lyell Board of Directors, stated, “The addition of Dr. Bachleda to the Lyell Board provides us with experienced commercial leadership, including in cell therapy, at this critical time as Lyell becomes a late-stage clinical company initiating pivotal clinical trials and anticipating a commercial launch of LYL314. I could not be more pleased with the progress the company is making and am confident that our new executive leaders will ensure operational excellence as we focus on rapidly advancing LYL314, our autologous CD19/CD20 CAR T-cell therapy, to patients.”

These appointments follow the earlier addition of Jarrad Aguirre, MD, MBA, who joined the company earlier this year as Senior Vice President of Medical Affairs. Collectively, these new leaders bring significant experience in clinical development, medical affairs, legal, and strategic oversight, further strengthening Lyell’s capabilities as it advances its pipeline of cell therapies aimed at improving outcomes for cancer patients.